Published in final edited form as:

Appl Immunohistochem Mol Morphol. 2018 February ; 26(2): e24–e25. doi:10.1097/PAI.0000000000000607.

Comprehensive Next-Generation Sequencing Analysis is Recommended for the Management of Patients With Melanoma

Keluo Yao, MD*, Weiqiang Zhao, MD, PhD*, Saeed Bajestani, MD*, Alejandro Gru, MD*, Gregory Otterson, MD†, Konstantin Shilo, MD*

*Department of Pathology, The Ohio State University Wexner Medical Center

†Division of Medical Oncology Department of Internal Medicine The Ohio State University Wexner Medical Center Columbus, Ohio

To the Editor:

We appreciate Dr Uguen's interest in our recent publication on the subject of thoracic melanoma (Yao et al).¹ In that manuscript, utilizing polymerase chain reaction–based and next generation sequencing based methods we document unique molecular profiles of this aggressive malignancy. We note the suggestion for targeted testing of melanoma for *BRAF* and *NRAS* mutations, which provide efficiency and practicality in management of such cases. Nevertheless, as the field of tumor genetics is still being developed, we strongly advocate molecular profiling of cutaneous and noncutaneous melanoma utilizing NGS methods as it lays ground for insight into molecular makeup and identification of new potential targets for therapy.^{2,3}

REFERENCES

1. Yao K, Zhao W, Bajestani S, et al. Malignant melanoma presenting as thoracic midline malignancy: clinicopathologic and molecular features. *Appl Immunohistochem Mol Morphol*. 2017 Doi:10.1097/PAI.0000000000000546. [Epub ahead of print].
2. de Unamuno Bustos B, Estal R, Simo G, et al. Towards personalized medicine in melanoma: implementation of a clinical next-generation sequencing panel. *Sci Rep*. 2017;7:495–506. [PubMed: 28356599]
3. Griewank KG, Bastian S. Next-generation sequencing to guide treatment of advanced melanoma. *Am J Clin Dermatol*. 2017;18: 303–310. [PubMed: 28229402]